Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ...

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”), the leading autologous (patient’s own) stem cell ...

New pooled data confirm that endovascular thrombectomy improves survival and function in large-core stroke, offering hope for ...

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from a sex-specific analysis of 160 real-world ...

A bioadaptor implant adaptable to vessel physiology was linked to less target lesion failure and target vessel failure ...

The critical first 90 days post-stroke are vital for recovery, offering a prime window for brain repair and adaptation. Early ...

Functional recovery after EVT for AIS varies by race and ethnicity, even though procedural success is similar across groups.

Transcatheter arterialization of the deep veins for chronic limb-threatening ischemia in no-option patients kept most ...

Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first monthThe Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, ...

BACKGROUND: A 3-dimensional hyperboloid model has been proposed to characterize ventricular tachycardia (VT) circuitry. We ...

The VasCog-2-WSO criteria revise the original VasCog criteria for diagnosing VCID, offering additional guidance on neuroimaging and fluid biomarkers.